@article{1f13aff268b34bb7a4aa8abe90b3b13b,
title = "Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014-2016",
abstract = "The purpose of this study is to validate the seven-item wheezing module from the International Study of Asthma and Allergies in Children (ISAAC) in the nationally representative Population Assessment of Tobacco and Health Study. Adult participants with complete Wave 2–3 data were selected, including those with asthma but excluding those with COPD and other respiratory diseases (n = 16,295). We created a nine-point respiratory symptom index from the ISAAC questions, assessed the reliability of the index, and examined associations with self-reported asthma diagnosis. Threshold values were assessed for association with functional outcomes. The weighted prevalence for one or more respiratory symptom was 18.0% (SE = 0.5) for adults without asthma, 70.1% (SE = 1.3) for those with lifetime asthma, 75.7% (SE = 3.7) for adults with past-year asthma not on medi-cations, and 92.6% (SE = 1.6) for those on medications. Cronbach{\textquoteright}s alpha for the respiratory symptom index was 0.86. Index scores of ≥2 or ≥3 yielded functionally important respiratory symptom prevalence of 7–10%, adequate sensitivity and specificity for identifying asthma, and consistent in-dependent associations with all functional outcomes and tobacco use variables. Respiratory symptom index scores of ≥2 or ≥3 are indicative of functionally important respiratory symptoms and could be used to assess the relationship between tobacco use and respiratory health.",
keywords = "Functional outcomes, PATH Study, Patient-reported outcomes, Respiratory health, Tobacco use, Wheeze",
author = "Halenar, {Michael J.} and Sargent, {James D.} and Edwards, {Kathryn C.} and Steven Woloshin and Lisa Schwartz and Jennifer Emond and Susanne Tanski and Pierce, {John P.} and Taylor, {Kristie A.} and Kristin Lauten and Goniewicz, {Maciej L.} and Raymond Niaura and Gabriella Anic and Yanling Chen and Priscilla Callahan-Lyon and Gardner, {Lisa D.} and Theresa Thekkudan and Nicolette Borek and Kimmel, {Heather L.} and Cummings, {K. Michael} and Andrew Hyland and Brunette, {Mary F.}",
note = "Funding Information: Funding: This manuscript is supported with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, and the Center for Tobacco Products, Food and Drug Administration (FDA), Department of Health and Human Services, under contract to Westat (Contract No. HHSN271201100027C. Funding Information: Conflicts of Interest: K.M.C. provides expert testimony on the health effects of smoking and tobacco industry tactics in lawsuits filed against the tobacco industry. He has also received payment as a consultant to Pfizer, Inc., for services on an external advisory panel to assess ways to improve smoking cessation delivery in health care settings. M.L.G. has received a research grant from Pfizer and served as a member of scientific advisory board to Johnson & Johnson, pharmaceutical companies that manufacture smoking cessation medications. R.N. receives funding from the Food and Drug Administration Center for Tobacco Products via contractual mechanisms with Westat and the National Institutes of Health. Within the past 3 years, he has served as a paid consultant to the Government of Canada via a contract with Industrial Economics Inc. and has received an honorarium for a virtual meeting from Pfizer Inc. He was an unpaid grant reviewer for the Foundation for a Smoke Free World. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = sep,
doi = "10.3390/ijerph18189688",
language = "English (US)",
volume = "18",
journal = "International Journal of Environmental Research and Public Health",
issn = "1661-7827",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "18",
}